Scope
NICE NG99 covers investigation, treatment decisions, follow-up and supportive care for glioma, meningioma and brain metastases in people over 16. The recommendations emphasize multidisciplinary interpretation of imaging and pathology, maximal safe local treatment where appropriate, and decisions shaped by tumour biology and functional status. This selected summary preserves the guideline’s tumour-specific criteria rather than treating all brain tumours as one pathway.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Establish imaging and molecular diagnosis
- Offer standard structural MRI for suspected glioma, meningioma or brain metastases unless contraindicated. Refer suspected glioma to the specialist multidisciplinary team at the first radiological diagnosis. [1]
- Report glioma specimens using the latest WHO classification with histological and molecular assessment. Test high-grade glioma for MGMT promoter methylation to inform prognosis and treatment. [1]
- Consider advanced MRI when a lesion appearing low grade may have high-grade transformation. For suspected meningioma, consider CT if bone involvement is suspected and has not already been assessed. [1]
- For suspected brain metastases potentially suitable for focal treatment, obtain extracranial staging appropriate to the primary tumour. Complete intracranial and extracranial imaging, and extracranial biopsy when appropriate, before neuro-oncology multidisciplinary referral. [1]
Initial low-grade glioma decisions
- For suspected low-grade glioma, consider resection within 6 months of radiological diagnosis to establish histological and molecular diagnosis and remove as much tumour as safely possible. Discuss the achievable extent with the team and patient; consider biopsy when resection is inappropriate. [1]
- For radiologically typical very low-grade lesions, consider monitoring without histological diagnosis. If clinical or imaging progression occurs, return to multidisciplinary review and consider resection or biopsy when resection is impossible. [1]
- After surgery, offer radiotherapy followed by up to 6 PCV cycles for IDH-mutated, 1p/19q-codeleted low-grade glioma when the person is around 40 or older or has residual tumour. For non-codeleted IDH-mutated low-grade glioma with these features, consider that approach. [1]
- Consider active monitoring for an IDH-mutated low-grade glioma in someone around 40 or younger with no postoperative residual tumour. Subsequent treatment choices depend on progression, symptoms and previous radiotherapy. [1]
High-grade glioma treatment and reassessment
- For newly diagnosed glioblastoma after maximal safe resection, or biopsy when resection is not possible, offer 60 Gy in 30 fractions with concomitant temozolomide and up to 6 adjuvant cycles when age is around 70 or younger and Karnofsky performance status is at least 70. [1]
- In people around 70 or older with Karnofsky status at least 70, offer 40 Gy in 15 fractions with concomitant and up to 12 adjuvant temozolomide cycles for newly diagnosed MGMT-methylated glioblastoma. Consider this regimen when methylation is absent or unavailable. [1]
- Consider supportive care alone for glioblastoma in people around 70 or older with Karnofsky status below 70. Reassess postoperative performance status and revisit treatment options when it changes. [1]
- For recurrent high-grade glioma, weigh performance status, preferences, elapsed time, molecular markers and previous treatment. Consider supportive care alone when further treatment is unlikely to help or is not wanted; focal recurrence also warrants consideration of further surgery or radiotherapy. [1]
Meningioma and brain metastases
- Base meningioma management on tumour grade and extent of excision. Before radiotherapy, assess neurological function, progression, size and location, prior treatment, expected morbidity, life expectancy and patient preferences. [1]
- For a single brain metastasis, consider maximal local treatment with surgery, stereotactic radiosurgery or stereotactic radiotherapy. Choose with the patient, considering comorbidities, oedema, location and size; do not offer adjuvant whole-brain radiotherapy after these treatments. [1]
- Consider stereotactic treatment for multiple brain metastases when extracranial disease is controlled or controllable and Karnofsky status is at least 70. Account for both number and total volume of metastases. [1]
- Do not offer whole-brain radiotherapy for non-small-cell lung cancer with brain metastases unsuitable for surgery or stereotactic treatment when Karnofsky status is below 70. For other patients with multiple metastases untreated locally, discuss benefits and harms before deciding on whole-brain treatment. [1]
Follow-up, support and late effects
- Arrange clinical review and suitable imaging whenever new or changing neurological symptoms develop in glioma, meningioma or brain metastases. Consider postoperative baseline MRI within 72 hours after glioma resection and another baseline 3 months after radiotherapy. [1]
- Provide a named coordinator and supportive care throughout treatment and follow-up. Discuss fertility preservation if treatment could impair fertility, and consider neurological rehabilitation assessment at diagnosis and each follow-up stage. [1]
- At treatment completion, document and explain individual risks of late effects. Consider ongoing neuropsychology assessment for cognitive risk and regular endocrine assessment if radiotherapy may have affected pituitary function. [1]
Limitations and use
- This summarizes NICE NG99, published in 2018 and updated in January 2021; it is not a new international consensus or a complete oncology regimen. Tumour terminology and technology-appraisal links should be read with the current classification and local treatment access.
- Detailed grade-specific meningioma tables, surveillance schedules and all linked technology appraisals are not reproduced. UK commissioning and legal arrangements are context-specific.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Brain tumours (primary) and brain metastases in over 16s
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 11 July 2018
- Publisher’s latest update
- 29 January 2021
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- United Kingdom
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.